NUAK1 and ovarian carcinoma: Downregulation of NUAK1 Does Not Sensitize SOC to Cisplatin or Paclitaxel, but Does Attenuate the Migratory Potential of Chemosensitive and Resistant Ovarian Cancer Cells In Vitro